Compare Enveric Biosciences Inc (ENVB) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nokia Corp — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Nokia Corp trades at $9.54 (market cap $51.87B). The key difference: Nokia Corp is far larger — about 8366.1× Enveric Biosciences Inc's market cap, and Nokia Corp pays a 1.79% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NOK | |
|---|---|---|
Market Cap | $6.20M | $51.87B |
Sector | Health | Technology |
52-Week High | $17.40 | $16.83 |
52-Week Low | $1.27 | $4.13 |
Enterprise Value | $1.30M | $49.82B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Nokia (NOK) trades at $9.37, down 0.53% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue for 2025 was $19.89B, with a net income margin of 3.47%. Analyst consensus is 60% buy, supported by strong cash flow from operations of $2.07B in 2025 and a focus on AI and cloud infrastructure growth.
Outlook is cautiously optimistic due to AI demand boosting earnings, but risks include telecom spending volatility and high P/E of 67.5. The stock offers growth potential from AI networking, yet investors face margin pressures and competitive threats in the telecom equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
